Results 181 to 190 of about 1,878,157 (376)
ABSTRACT Introduction Prevalence estimates and correlates of ARFID in non‐Western samples are lacking. This study aims to estimate the prevalence of ARFID symptoms, identify its phenotypes, and explore its correlates in a community sample from the Gulf Cooperation Council (GCC).
Bernou Melisse+8 more
wiley +1 more source
Linguistic and metalinguistic characteristics of Persian-speaking children with autistic spectrum disorders: A systematic review. [PDF]
Ahadi H, Abbasi H, Fekar Gharamaleki F.
europepmc +1 more source
ABSTRACT Objective Residential treatment for eating disorders addresses the gap between inpatient and outpatient care, but evidence for longer‐term and functional outcomes remains limited. The current study examined both clinical and functional outcomes from admission to a 6‐month follow‐up from Australia's first residential service for eating ...
Sinead Day+10 more
wiley +1 more source
Review: vaccines containing thimerosal are not associated with autistic spectrum disorders in children [PDF]
William M. McMahon
openalex +1 more source
Gamified Environments and Serious Games for Students With Autistic Spectrum Disorder: Review of Research. [PDF]
López-Bouzas N, Del Moral-Pérez ME.
europepmc +1 more source
ABSTRACT Objective Avoidant restrictive food intake disorder (ARFID) is a relatively new diagnostic entity, and no medication has been approved. Recent data suggest that mirtazapine, a tetracyclic antidepressant, could improve outcomes in ARFID. We conducted a retrospective chart review to examine the effects of mirtazapine on ARFID treatment in youth.
Aman Chishti+6 more
wiley +1 more source
Antiepileptic Drugs in Autistic Spectrum Disorders
J Gordon Millichap
openalex +2 more sources
Serum Amino Acid Profiling in Children with Autistic Spectrum Disorder: Insights from a Single-Center Study in Southern Romania. [PDF]
Anastasescu CM+9 more
europepmc +1 more source
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons+17 more
wiley +1 more source
Hyperlexia in a 4-year-old boy with Autistic Spectrum Disorder [PDF]
Keith Atkin, Marjorie Perlman Lorch
openalex +1 more source